The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Immunotherapies currently under investigation for CLL
Alexey V. Danilov, MD, PhD, City of Hope, Duarte, CA, shares some insights into immunotherapeutic agents under investigation for the treatment of chronic lymphocytic leukemia (CLL), commenting on their importance for patients who progress after BTK inhibitors. Prof. Danilov first discusses the promise of CAR-T therapy, and then goes on to highlight the potential use of bispecific T-cell engagers (BiTEs) and natural killer (NK) CARs, and ongoing studies evaluating these agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
